Core Viewpoint - The article highlights the upcoming deadline of April 3, 2026, for investors to file a lead plaintiff motion in a class action lawsuit concerning Picard Medical, Inc. (NYSE American: PMI) securities, which were acquired between September 2, 2025, and October 31, 2025 [1]. Group 1 - The class action is filed on behalf of investors who purchased or acquired Picard Medical securities during the specified class period [1]. - Investors who suffered losses on their Picard investments are encouraged to inquire about potential participation in the lawsuit [1].

Core Viewpoint - The Law Offices of Frank R. Cruz is reminding investors about the January 26, 2026 deadline to participate as lead plaintiffs in a securities fraud class action lawsuit against Sprouts Farmers Market, Inc. for losses incurred during the specified class period [1] Group 1 - The lawsuit is on behalf of investors who acquired Sprouts Farmers Market, Inc. securities between June 4, 2025, and October 29, 2025 [1] - The company is listed on NASDAQ under the ticker symbol SFM [1]

Core Viewpoint - Bitdeer Technologies Group is facing a class action lawsuit due to significant financial losses and misleading statements regarding its product development, particularly the Seal 04 ASIC chip [2][4]. Financial Performance - On November 10, 2025, Bitdeer reported a per-share loss of $1.28 for Q3 2025, which was significantly worse than the expected loss of $0.22 [2]. - Following the announcement, Bitdeer's stock price dropped by $2.63, or 14.9%, closing at $15.02 per share on November 11, 2025, impacting investors negatively [3]. Lawsuit Details - The class action lawsuit alleges that Bitdeer made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period from June 6, 2024, to November 10, 2025 [4]. - Specifically, the lawsuit claims that Bitdeer misrepresented the readiness and efficiency of the SEAL04 chip, which was projected to have a chip-level energy efficiency of 5 J/TH and was expected to begin mass production in Q2 2025 [4]. Investor Actions - Investors who purchased Bitdeer securities during the class period can file a lead plaintiff motion by February 2, 2026, to participate in the class action lawsuit [5].

Core Viewpoint - Bath & Body Works, Inc. is facing a class action lawsuit due to significant declines in financial performance and misleading statements regarding its business strategy during the class period from June 4, 2024, to November 19, 2025 [1][7]. Financial Performance - On August 28, 2025, Bath & Body Works reported Q2 2025 earnings per diluted share of $0.30, a decline of 55.8% year over year, and net income of $64 million, down 57.9% year over year [3]. - The company cut its full-year guidance for earnings per diluted share by $0.03, adjusting it to a range of $3.28 to $3.53 [3]. - On November 20, 2025, the company reported Q3 2025 revenue declined by 1% year over year, missing guidance of 1-3% growth, and net income fell 26% to $77 million [5]. - The full-year guidance for net sales was slashed from a previously positive 1.5%-2.7% to a negative "high single digits," and expected earnings per diluted share were reduced to "at least $2.83" [5]. Stock Performance - Following the Q2 2025 results announcement, Bath & Body Works' stock price fell by $2.18, or 6.9%, closing at $29.36 per share on August 28, 2025 [4]. - After the Q3 2025 results, the stock price dropped by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [6]. Lawsuit Details - The class action lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations [7]. - Specific allegations include the failure of the company's strategy of "adjacencies, collaborations and promotions" to grow the customer base and the reliance on brand collaborations to mask weak financial results [7]. - The lawsuit claims that the company was unlikely to meet its previously issued financial guidance due to these issues [7]. Participation in the Lawsuit - Investors who purchased Bath & Body Works securities during the class period can file a lead plaintiff motion by March 16, 2026, if they meet certain legal requirements [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the Class Period from November 4, 2024, to October 3, 2025, of the January 16, 2026, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by January 16, 2026 [2]. - The lawsuit claims that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, of the January 12, 2026, deadline to become lead plaintiffs in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Freeport-McMoRan securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiffs must act by January 12, 2026 [3]. - The lawsuit alleges that Freeport-McMoRan made false or misleading statements regarding safety at the Grasberg Block Cave mine in Indonesia, which led to increased risks for workers and potential damages for investors [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Freeport-McMoRan is a prominent mining company with a positive outlook from Morgan Stanley, despite facing legal challenges related to a securities fraud lawsuit [2][3][5]. Group 1: Company Overview - Freeport-McMoRan is recognized for its substantial copper and gold production, operating large, long-lived, and geographically diverse assets with significant reserves of copper, gold, and molybdenum [1]. - The company has a market capitalization of approximately $68.27 billion, indicating its strong presence in the mining sector [5]. Group 2: Stock Performance - As of December 15, 2025, Freeport-McMoRan's stock price is $47.55, reflecting a slight increase of 0.35% or $0.17, with fluctuations between a low of $47.39 and a high of $48.85 on that day [4][6]. - Over the past year, the stock has experienced a high of $49.12 and a low of $27.66, showcasing volatility in its performance [4]. Group 3: Analyst Ratings - Morgan Stanley has maintained an "Overweight" rating for Freeport-McMoRan, raising its price target to $53 from a previous target of $44, indicating confidence in the company's future performance [2][6]. - The positive rating from Morgan Stanley suggests potential growth opportunities for the company despite existing legal challenges [5]. Group 4: Legal Challenges - Freeport-McMoRan is currently facing a securities fraud lawsuit, with a reminder issued to investors who purchased FCX securities between February 15, 2022, and September 24, 2025, to apply as lead plaintiffs by January 12, 2026 [3][6].

Core Viewpoint - Gauzy Ltd. is facing legal action due to alleged securities fraud, with a deadline for investors to file a lead plaintiff motion by February 6, 2026 [1][6]. Group 1: Company Situation - On November 14, 2025, Gauzy announced that the Commercial Court of Lyon, France, ordered insolvency proceedings for three of its subsidiaries in France, which are aimed at preserving the business and operations while repaying creditors [3]. - The commencement of these insolvency proceedings constitutes a default under the Company's existing senior secured debt facilities, potentially leading to further defaults if not remedied [3]. - The Company will not release its third-quarter financial results as previously planned due to these proceedings [3]. Group 2: Market Reaction - Following the announcement of the insolvency proceedings, Gauzy's share price fell by $2.00 per share, or 49.8%, closing at $2.02 per share on November 17, 2025, with unusually heavy trading volume [4]. Group 3: Lawsuit Details - The class action lawsuit alleges that during the Class Period, the Defendants made materially false and misleading statements and failed to disclose adverse facts about the Company's financial situation, including the inability of its French subsidiaries to meet their debts [5]. - The lawsuit claims that the Defendants' positive statements regarding the Company's business and prospects were materially misleading and lacked a reasonable basis due to the impending insolvency [5].

Core Insights - Gauzy Ltd. (NASDAQ:GAUZ) is expected to report a quarterly earnings per share (EPS) of -$0.18 and revenue of approximately $32.8 million on December 12, 2025 [1][4] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of -0.61, indicating a lack of profitability [1][4] - A negative earnings yield of -1.63% further supports concerns regarding the company's ability to generate profits [1] - The price-to-sales ratio stands at 0.24, suggesting a low valuation relative to its revenue [1] - An enterprise value to sales ratio of 0.88 provides insight into GAUZ's valuation compared to its revenue [1] - The negative enterprise value to operating cash flow ratio of -4.25 indicates challenges in generating cash flow from operations [1] - A high debt-to-equity ratio of 3.54 reflects significant financial risk due to elevated debt levels [1][4] - The current ratio of 0.66 suggests potential liquidity issues, as short-term liabilities may exceed short-term assets [2] Legal Issues - A class action lawsuit filed by Rosen Law Firm alleges securities fraud, targeting investors who purchased GAUZ securities between March 11, 2025, and November 13, 2025 [2][4] - This legal action may negatively impact investor confidence and the company's stock performance [3][4] - Shareholders who experienced financial losses are encouraged to contact Glancy Prongay & Murray LLP regarding the lawsuit, with a deadline for filing a lead plaintiff motion set for February 6, 2026 [3]

Core Viewpoint - The Law Offices of Howard G. Smith is urging investors of Primo Brands Corporation (PRMB) who suffered losses to participate in a class action lawsuit due to alleged securities fraud related to the company's merger and subsequent operational issues [1][5]. Summary by Sections Company Background - Primo Brands Corporation operates under the NYSE ticker PRMB and was formed following a merger between Primo Water Corporation and BlueTriton Brands, Inc. on November 8, 2024 [3]. Financial Performance and Stock Impact - On August 7, 2025, Primo Brands reported second quarter 2025 financial results, revealing that rapid facility closures and headcount reductions disrupted product supply and delivery, leading to a stock price drop of $2.41, or 9.1%, closing at $24.00 per share [3]. - Following the announcement on November 6, 2025, regarding the replacement of its CEO and a reduction in full-year 2025 net sales and adjusted EBITDA guidance, the stock price fell by $8.20, or 36.2%, closing at $14.46 per share on November 7, 2025 [4]. Lawsuit Details - The class action lawsuit alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose significant operational issues, including poor merger integration and major supply disruptions that negatively impacted financial results [5][6]. - Investors who purchased Primo Brands common stock during the specified class period (November 11, 2024, to November 6, 2025) are encouraged to file a lead plaintiff motion by January 12, 2026, if they meet legal requirements [1][6].